ALECTOR INC (ALEC)
US0144421072 - Common Stock
Taking everything into account, ALEC scores 3 out of 10 in our fundamental rating. ALEC was compared to 565 industry peers in the Biotechnology industry. The financial health of ALEC is average, but there are quite some concerns on its profitability. ALEC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ALEC has reported negative net income.
ALEC had a negative operating cash flow in the past year.
ALEC had negative earnings in each of the past 5 years.
In the past 5 years ALEC reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of ALEC (-30.70%) is better than 67.08% of its industry peers.
The Return On Equity of ALEC (-133.19%) is worse than 62.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.7% | ||
| ROE | -133.19% | ||
| ROIC | N/A |
ROA(3y)-14.12%
ROA(5y)-21.26%
ROE(3y)-57.15%
ROE(5y)-59.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALEC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALEC has more shares outstanding
Compared to 5 years ago, ALEC has more shares outstanding
ALEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.27, we must say that ALEC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.27, ALEC perfoms like the industry average, outperforming 51.07% of the companies in the same industry.
ALEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.27 |
ROIC/WACCN/A
WACC11%
2.3 Liquidity
ALEC has a Current Ratio of 3.29. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.29, ALEC is not doing good in the industry: 60.14% of the companies in the same industry are doing better.
A Quick Ratio of 3.29 indicates that ALEC has no problem at all paying its short term obligations.
ALEC's Quick ratio of 3.29 is in line compared to the rest of the industry. ALEC outperforms 41.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 |
3. Growth
3.1 Past
ALEC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.59%.
The Revenue for ALEC has decreased by -36.06% in the past year. This is quite bad
The Revenue has been growing by 28.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-0.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.87%
Revenue 1Y (TTM)-36.06%
Revenue growth 3Y66.31%
Revenue growth 5Y28.5%
Sales Q2Q%68.43%
3.2 Future
The Earnings Per Share is expected to grow by 7.43% on average over the next years.
Based on estimates for the next years, ALEC will show a small growth in Revenue. The Revenue will grow by 3.49% on average per year.
EPS Next Y-20.43%
EPS Next 2Y-3.95%
EPS Next 3Y1.63%
EPS Next 5Y7.43%
Revenue Next Year-31.08%
Revenue Next 2Y8.78%
Revenue Next 3Y5.82%
Revenue Next 5Y3.49%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALEC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALEC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.95%
EPS Next 3Y1.63%
5. Dividend
5.1 Amount
No dividends for ALEC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALECTOR INC
NASDAQ:ALEC (12/27/2024, 8:00:00 PM)
After market: 1.75 -0.03 (-1.69%)1.78
-0.04 (-2.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners86.01%
Inst Owner Change-1.06%
Ins Owners7.33%
Ins Owner Change12.79%
Market Cap174.32M
Analysts78.82
Price Target8.03 (351.12%)
Short Float %6.12%
Short Ratio4.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.36%
Min EPS beat(2)21%
Max EPS beat(2)21.73%
EPS beat(4)4
Avg EPS beat(4)26.76%
Min EPS beat(4)21%
Max EPS beat(4)37.69%
EPS beat(8)7
Avg EPS beat(8)28.27%
EPS beat(12)8
Avg EPS beat(12)-9.58%
EPS beat(16)11
Avg EPS beat(16)-8.54%
Revenue beat(2)1
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-4.18%
Max Revenue beat(2)2.7%
Revenue beat(4)3
Avg Revenue beat(4)14.59%
Min Revenue beat(4)-4.18%
Max Revenue beat(4)54.54%
Revenue beat(8)5
Avg Revenue beat(8)137.07%
Revenue beat(12)6
Avg Revenue beat(12)88.4%
Revenue beat(16)6
Avg Revenue beat(16)58.45%
PT rev (1m)-42.73%
PT rev (3m)-42.73%
EPS NQ rev (1m)0.81%
EPS NQ rev (3m)-13.21%
EPS NY rev (1m)2.33%
EPS NY rev (3m)4.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.47 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.7
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.26
OCFYN/A
SpS0.63
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.7% | ||
| ROE | -133.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-14.12%
ROA(5y)-21.26%
ROE(3y)-57.15%
ROE(5y)-59.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 24.38% | ||
| Cap/Sales | 2.22% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.29 | ||
| Altman-Z | -2.27 |
F-Score1
WACC11%
ROIC/WACCN/A
Cap/Depr(3y)54.77%
Cap/Depr(5y)130.34%
Cap/Sales(3y)2.36%
Cap/Sales(5y)20.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.87%
EPS Next Y-20.43%
EPS Next 2Y-3.95%
EPS Next 3Y1.63%
EPS Next 5Y7.43%
Revenue 1Y (TTM)-36.06%
Revenue growth 3Y66.31%
Revenue growth 5Y28.5%
Sales Q2Q%68.43%
Revenue Next Year-31.08%
Revenue Next 2Y8.78%
Revenue Next 3Y5.82%
Revenue Next 5Y3.49%
EBIT growth 1Y-14.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.21%
EBIT Next 3Y6.18%
EBIT Next 5Y-3.5%
FCF growth 1Y-807.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-972.52%
OCF growth 3YN/A
OCF growth 5YN/A